
News briefing: Boehringer Ingelheim expands protein degradation efforts; Pfizer enlists a new AI partner
Boehringer Ingelheim is expanding its efforts in protein degradation, signing a pact with the Austrian biotech Proxygen to develop a technology known as “molecular glue degraders.”
Similar to the PROTACS that companies have focused on to date, molecular glue degraders are designed to bridge proteins to the body’s own internal disposal system, allowing researchers to target proteins that can’t be hit by traditional small molecules. The multiple myeloma drugs Revlimid and Pomalyst work in this manner. Founded in 2016, Proxygen has worked to develop methods of systematically finding new ones.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters